DPP4 inhibitors is expected for the corrective effect of circadian blood sugar fluctuations and postprandial hyperglycemia. We were administered Vildagliptin(VG) to the patients with T2DM, and observed changes in the arterial stiffness in conjunction with the variation in glucose metabolism.Design and Method:
WE enrolled 20 patients (8 males, 12 females) with T2DMwho were administered VG 50 mg each morning and evening after meals in addition to the existing treatment. Observation period was 6 months. We measured and evaluated the fasting blood sugar, HbA1c, 1,5-AG, and CAVI, as an arterial stiffness parameter. Reactive Oxygen Metabolites (dROMs) as oxidative stress marker, and preheparin LPLmass (LPL) as insulin sensitivity marker were measured. Blood glucose were measured six times daily to calculate the M value for quantifying blood glucose variability range.Results:
HbA1c is significantly reduced from 8.5 ± 2.2 to 6.7 ± 0.9, 1,5-AG is significantly improved from 6.8 ± 4.9 to 12.0 ± 5.8, CAVI is significantly improved from 9.0 ± 1.1 to 8.6 ± 1.0 (p = 0.044). dROMs has a tendency to slight improvement from 392.1 ± 4.1 to 382.9 ± 66.3, also LPL tend to improve from 60.0 ± 19.6 to 63.1 ± 19.4. M value was improved from 17.3 to 9.9.Conclusions:
In the single-correlation analysis the amount of change in CAVI and dROMs, CAVI is a tendency to improvement was observed by the improvement of dROMs (p = 0.1065). In addition, in the analysis of the amount of change in CAVI and LPL, we observed correlation of significant positive in improvement of the LPL and CAVI (p = 0.0022). CAVI was significantly improved by administration of VG in this study. By the administration of VG, tendency of improvment of oxidative stress and insulin sensitivity was observed. It is suggesting that these mechanisms improving arterial stiffness.